SCHEMBL3595659

SCHEMBL3595659

CN(CCNC(=O)Cn1ccc2c(-c3ccc(F)cc3)cccc21)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
GRIN2B Q13224 8/20 0.40
ALDH1A1 P00352 1/20 0.38
MAPK1 P28482 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 3/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TP53 P04637 2/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
POLB P06746 1/20 0.37
THRB P10828 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
CCKBR P32239 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603569 0.92 MAPT (0.41) MEN1KMT2AGAATSHRGRIN2B
SCHEMBL3603866 0.87 MEN1 (0.45) MEN1KMT2AGAATSHRALDH1A1
SCHEMBL3608258 0.86 GAA (0.43) MEN1KMT2AGAATSHRGRIN2B
SCHEMBL3598309 0.84 SMN1; SMN2 (0.43) MEN1KMT2AGAATSHRHSD17B10
SCHEMBL3595662 0.83 GRIN2B (0.46) MEN1KMT2AGRIN2BMAPTPOLB
SCHEMBL3588045 0.82 GRIN2B (0.45) GRIN2BMAPTTP53
SCHEMBL3600289 0.82 GRIN2B (0.47) GAATSHRGRIN2BALDH1A1HSD17B10
SCHEMBL3606203 0.81 CYP2D6 (0.45) MEN1KMT2AGAATSHRGRIN2B
SCHEMBL3600780 0.80 GRIN2B (0.46) GAATSHRGRIN2BALDH1A1HSD17B10
SCHEMBL3595020 0.79 HSD17B10 (0.52) KMT2AGAATSHRALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed
WO-2007115231-A2 CXCR4 MODULATORS CHEMOCENTRYX, INC. (US) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 MEN1 4362/4885KMT2A 3838/4885GAA 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.